Navigation Links
Researchers identify new cell targets for preventing growth of breast and other tumors

CHAPEL HILL Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.

This step the creation of new blood vessels enables tumors to grow out of control and ultimately spread cancer to other parts of the body.

Targeting blood vessel formation, or angiogenesis, promises to be less toxic than the standard chemotherapy approach that kills cancer cells and normal cells alike. The new tactic has been shown by others to be successful in the treatment of breast cancer and colon cancer with the drug bevacizumab (commercially known as Avastin), which inhibits an important player in angiogenesis, a protein called vascular endothelial growth factor (VEGF).

There is a large amount of data that shows if you block angiogenesis, you can block tumor growth, said Dr. Nancy Klauber-DeMore, associate professor of surgery in the UNC School of Medicine and senior author on the study. But VEGF is not responsible for all of angiogenesis. We wanted to identify more targets for this therapeutic approach.

The most exciting aspect of this study is that we now have a very large list of potential targets that we will continue to work on for at least the next decade, Klauber-DeMore said.

A report of the study appeared online this month in the American Journal of Pathology. It will be published in the May 2008 print edition of the journal.

Angiogenesis only occurs normally in a few instances, such as wound healing, female reproduction and fetal development. But it also plays an important role in the growth and spread of cancer. New blood vessels provide essential nourishment to cancer cells, allowing them to grow, travel to other parts of the body and form new cancers.

Because tumors cannot grow or spread without the formation of new blood vessels, Klauber-DeMore sought new targets that are produced in excess (overexpressed) on tumor blood vessels. The hope is that by identifying proteins on these vessels, new drugs may be developed that block these proteins and put a stop to tumor blood vessel growth.

In a technique that took three years to perfect, the UNC researchers microdissected individual vascular cells from frozen sections of five cancerous and five normal breast tissue samples. They scanned the activity of thousands of genes in the isolated cells and then compared the gene activity between the tumor and normal vascular samples. They found 1,176 genes that differed in activity or expression between the two cell populations. Of these, 55 genes were overexpressed more than four-fold in blood vessels from breast cancer.

Because proteins that either lie on the cell surface or are secreted from the cell are the easiest targets for drug development, the researchers searched a database to pinpoint the likely cellular location of the proteins encoded by the candidate genes. They found that seven of the genes encoded membrane or secreted proteins. Four of these namely FAP, SFRP2, JAK3 and SMPD3 had not just increased gene expression, but also increased protein expression in breast tumor vessels, and thus could be good targets for the development of novel cancer therapies.

The researchers need to do further research to accurately define whether these proteins induce angiogenesis, Klauber-DeMore said. They can then design new compounds and test existing ones to see if they inhibit tumor growth.

Weve only looked at seven out of a list of 55 potential targets, Klauber-DeMore said. This work points us in the direction we need to go to develop the next generation of angiogenesis inhibitors.

Klauber-DeMore said that other researchers, led by George Coukos at Fox Chase Cancer Center, are trying the same approach with ovarian cancer, suggesting that this strategy may be applicable to many different tumor types.


Contact: Dianne Shaw
University of North Carolina at Chapel Hill

Related medicine news :

1. Melanoma lurks in larger skin lesions, NYU researchers find
2. Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers
3. MU researchers reveal communication tactics used by sexual predators to entrap children
4. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
5. MU researchers find clue to cataract formation
6. Researchers evaluating food allergy treatment
7. U of M researchers identify process that may help treat Parkinsons, spinal cord injuries
8. OHSU Cancer Institute researchers discover key gene involvement in cancer development
9. Combining liver cancer treatments doubles survival rates, UVA researchers find
10. Leading HIV researchers to collaborate on vaccine development
11. Georgetown researchers find stem cell marker controls 2 key cancer pathways
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... health professionals, announced today its affiliation with Tennessee Counseling Association. This ... the network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. ...
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Australia,s successful biotechnology scientists, Dr Graham ... Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is seeking ... ASX. Noxopharm is a clinic-ready company with its first ... study later this year. NOX66 ... cancer patients - the ability of cancers to become resistant to ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: